Related references
Note: Only part of the references are listed.Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models
Bingyi Yang et al.
PLOS ONE (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Phase 2 Trial of the Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Patients With Retinoblastoma Protein-Expressing Germ Cell Tumors
David J. Vaughn et al.
CANCER (2015)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele et al.
CLINICAL CANCER RESEARCH (2015)
Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model
Karen E. Parrish et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Targeting cell cycle and hormone receptor pathways in cancer
C. E. S. Comstock et al.
ONCOGENE (2013)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
G. K. Schwartz et al.
BRITISH JOURNAL OF CANCER (2011)
Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Gottfried E. Konecny et al.
CLINICAL CANCER RESEARCH (2011)
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
W. Ruprecht Wiedemeyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Tailoring to RB: tumour suppressor status and therapeutic response
Erik S. Knudsen et al.
NATURE REVIEWS CANCER (2008)
Cell cycle control in breast cancer cells
CE Caldon et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer
G Ferrandina et al.
GYNECOLOGIC ONCOLOGY (2005)
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
PL Toogood et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Share Paper
